300238.SHE Guanhao Biotech Co Ltd
- Market cap
- CNY 2.85B
- P/E
- 207.8x
- P/B
- 4.14x
- ROE
- 3.1%
- Dividend yield
- 0.13%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300238.SHE undervalued?
Graham numberThe Graham number of Guanhao Biotech Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guanhao Biotech Co Ltd fundamental analysis
No fundamental analysis for Guanhao Biotech Co Ltd yet.
Guanhao Biotech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guanhao Biotech Co Ltd
Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Type B dura, a spinal patch; Sterile Bio Wound Membrane; Ario Mesh; Thoracic Surg…
Full company profileGuanhao Biotech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guanhao Biotech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 313M | 461M | 458M | 438M | 437M | 489M | 377M | 404M | 377M | 383M | 334M |
| Gross Profit | 244M | 336M | 331M | 293M | 312M | 364M | 218M | 316M | 299M | 279M | 252M |
| Operating Income | 42.2M | 46.9M | 43.4M | -487M | 45.0M | 81.6M | -292M | 34.0M | 28.2M | 29.3M | 23.7M |
| EBITDA | 95.7M | 91.4M | 101M | -438M | 87.6M | 118M | -264M | 56.9M | 50.3M | 55.5M | 23.6M |
| Net Income | 57.0M | 45.5M | 45.7M | -465M | 46.6M | 73.7M | -308M | 31.0M | 27.4M | 24.3M | 21.3M |
| EPS | 0.23 | 0.17 | 0.17 | -1.75 | 0.18 | 0.28 | -1.16 | 0.12 | 0.10 | 0.09 | 0.08 |
| Balance Sheet | |||||||||||
| Total Assets | 1.69B | 1.72B | 1.64B | 1.15B | 1.13B | 1.10B | 670M | 679M | 754M | 807M | 857M |
| Total Liabilities | 231M | 505M | 484M | 445M | 418M | 351M | 239M | 222M | 287M | 301M | 268M |
| Shareholders' Equity | 1.39B | 1.17B | 1.15B | 711M | 730M | 784M | 485M | 521M | 542M | 570M | 681M |
| Cash & Short-term Investments | 325M | 278M | 105M | 140M | 156M | 159M | 126M | 105M | 107M | 161M | 223M |
| Total Debt | 80.0M | 325M | 298M | 268M | 208M | 151M | 79.1M | 48.6M | 103M | 127M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 30.7M | 19.2M | 32.3M | 92.5M | 104M | 122M | 71.0M | 54.1M | 49.6M | 71.5M | - |
| Capital Expenditure | 64.2M | 31.9M | 33.6M | 6.32M | 2.90M | 4.71M | 41.2M | 53.9M | 76.2M | 38.2M | 28.3M |
| Free Cash Flow | -33.5M | -12.7M | -1.37M | 86.2M | 101M | 118M | 29.8M | 231K | -26.6M | 33.3M | -40.1M |
| Ratios | |||||||||||
| ROE | 4.1% | 3.9% | 4.0% | -65.4% | 6.4% | 9.4% | -63.4% | 6.0% | 5.1% | 4.3% | 3.1% |
| ROA | 3.4% | 2.6% | 2.8% | -40.5% | 4.1% | 6.7% | -45.9% | 4.6% | 3.6% | 3.0% | 2.5% |
| Net Profit Margin | 18.2% | 9.9% | 10.0% | -106.3% | 10.7% | 15.1% | -81.6% | 7.7% | 7.3% | 6.3% | 6.4% |
| Debt to Equity | 0.06x | 0.28x | 0.26x | 0.38x | 0.28x | 0.19x | 0.16x | 0.09x | 0.19x | 0.22x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guanhao Biotech Co Ltd dividends
- Dividend yield
- 0.13%
- Forward dividend
- -
- Payout ratio
- 15.1%
- Ex-dividend date
- Jun 20, 2018
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 3.67M | 0.01 | 15.1% |
| 2024 | CNY 2.46M | 0.01 | 9.0% |
| 2023 | CNY 1.21M | 0.00 | 3.9% |
| 2022 | CNY 3.68M | 0.01 | - |
| 2021 | CNY 6.97M | 0.03 | 9.5% |
| 2020 | CNY 14.2M | 0.05 | 30.4% |
| 2019 | CNY 14.9M | 0.06 | - |
| 2018 | CNY 29.3M | 0.11 | 64.0% |
| 2017 | CNY 25.1M | 0.09 | 55.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Apr 16, 2015.
Who owns Guanhao Biotech Co Ltd
- Insiders 29.53%
- Institutions 2.42%
- Public & others 68.06%
- Shares outstanding 275M
- Free float 202M
Guanhao Biotech Co Ltd company profile
- Company name
- Guanhao Biotech Co Ltd
- Ticker
- 300238.SHE
- ISIN
- CNE100001575
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jul 6, 2011
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 535
- Fiscal year end
- December
- Address
- No. 12 Yuyan Road, Guangzhou, China, 510530
- Phone
- 86 20 3205 2806
- Website
- guanhaobio.com
About Guanhao Biotech Co Ltd
Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Type B dura, a spinal patch; Sterile Bio Wound Membrane; Ario Mesh; Thoracic Surgery Repair Diaphragm; and Cympic Benvimod Cream for psoriasis. In addition, it offers artificial lens and medical instruments; and cell technology services. Its products can be used in neurosurgery, thoracic general surgery, ophthalmology, dermatology, orthopedics, cosmetology, plastic surgery, and other areas. Guanhao Biotech Co.,Ltd. was founded in 1999 and is headquartered in Guangzhou, China.
Guanhao Biotech Co Ltd management
7- Mr. Feng ZhaoVice Chairman & GM · born 1978
- Ms. Junhui Zhao CPAExecutive VP & CFO · born 1976
- Mr. Xu QingrongDeputy GM & Secretary · born 1981
- Mr. Zhen YouDeputy General Manager · born 1981
- Mr. Weikun ZhangDeputy General Manager · born 1986
- Mr. Huaixin HouDeputy General Manager · born 1968
- Prof. Guofeng XuChief Technology Officer